Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity

AI Briefing

• – Novo Nordisk's Wegovy shows promising results
• – Higher-dose Wegovy achieves up to 28% weight loss in early responders
• – Weight loss mainly from fat, muscle preserved, according to new trial data